Monday, March 02, 2009

Genentech: Worth More Than Pfizer?

I am going to have to file this post under the Category of things I never thought I would be writing - but according to an blog post on the Forbes website last Friday - Genentech is worth more [in terms of Market Cap] than Pfizer.

Matthew Herper writes here that:

"Check this out: This morning, Genentech's market capitalization of $91 billion exceeds that of much-bigger Pfizer ($84 billion.) Pfizer has annual sales of $48 billion, compared to $13 billion for Genentech....Over the past two years, Genentech shares have been basically flat, but Pfizer's stock has plunged more than 40%."

Who would of thought this was possible?

Publish Post
Posted by at

1 comment:

Sally Church said...

Actually I think Genentech should be worth more than Pfizer. Why?

1) It has over 100 drugs in it's pipeline
2) It's oncology portfolio has been extremely successful
3) It has some of the best scientists in the business
4) It's nimble and has an excellent track record of bringing drugs to market over the last 10 years.

Pfizer? It's like a big dinosaur with heavy inward looking silos and a few winners such as Lipitor, but many missteps.

5:26 PM

Post a Comment

Subscribe to: Post Comments (Atom)